Osteopenia present. N Engl J Med. 2018;379(25):2407-2416. Level 1 [likely reliable] evidence Osteopenia places postmenopausal women at increased risk for fragility fracture, which can increase ...

With Gift Aid, your generous donation of £10 would be worth £12.50 at no extra cost to you. Yes, I want to Gift Aid any donations made to NAM now, in the future and in the past four years I am a UK ...

Denosumab is a monoclonal antibody which acts as a potent anti-resorptive agent and is now widely used in the treatment of osteoporosis. However, when treatment is discontinued, bone resorption ...

Giving zoledronate every 18 months for 6 years reduced the risk of fragility fractures—both vertebral and nonvertebral—in older women with hip bone mineral density indicating osteopenia, a ...

Editor's note: This story was updated on Oct. 23, to add conflict-of-interest disclosures for the lead author of the research study. A large study has produced strong evidence that a drug commonly ...

Although imatinib mesylate has revolutionized the treatment of chronic myeloid leukaemia (CML), resistance to the drug, manifesting as relapse after an initial response or persistence of disease, ...

The Health Outcomes and Reduced Incidence with Zoledronic Acid Once Yearly (HORIZON) Recurrent Fracture trial was an international, multicenter, randomized, double-blind, placebo-controlled trial of ...

Joo Hwan No, Fernando de Macedo Dossin, Yonghui Zhang, Yi-Liang Liu, Wei Zhu, Xinxin Feng, Jinyoung Anny Yoo, Eunhae Lee, Ke Wang, Raymond Hui, Lucio H. Freitas-Junior, Eric Oldfield Proceedings of ...

June 7, 2011 (Boston, Massachusetts) — Lower doses than are currently prescribed of the bisphosphonate zoledronate may be enough to increase bone density and reduce bone resorption in postmenopausal ...

To counter the decline in BMD after denosumab treatment is discontinued, osteoporosis patients may be transitioned from denosumab to other anti-resorptives. This report investigates whether a single ...

Zoledronate prevents fractures in older women when administered every 12 to 18 months, but its effects on bone density and bone turnover persist beyond 5 years. Whether infrequent zoledronate ...

BACKGROUND: Intravenous zoledronate 5 mg annually reduces fracture risk, and 5 mg every 2 years prevents bone loss, but the optimal dosing regimens for these indications are uncertain. METHODS: We ...